Chargement en cours...
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting
Despite significant progress in the prevention of chemotherapy-induced nausea and vomiting (CINV) with the introduction of new antiemetic agents, 30–50% of patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC) and guideline directed prophylactic antiemetics develop breakthroug...
Enregistré dans:
| Publié dans: | Biomed Res Int |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Hindawi Publishing Corporation
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4573228/ https://ncbi.nlm.nih.gov/pubmed/26421294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/595894 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|